Brown Advisory
CARM

Brown Advisory’s Carisma Therapeutics CARM Stock Holding History

Brown Advisory’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,044
Closed -$30K – 1321
2018
Q4 		$30K Hold
1,044
– – ﹤0.01% 1233
2018
Q3 		$45K Sell
1,044
-361
-26% -$14.1K ﹤0.01% 1316
2018
Q2 		$55K Buy
+1,405
New +$61.9K ﹤0.01% 1265

Other funds holding CARM

KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Brown Advisory's CARM Position: Q1 2019 in Review

Brown Advisory sold out of Carisma Therapeutics (CARM) in Q1 2019, closing a stake of 1,044 shares — an estimated $30K sold.

Brown Advisory first reported a position in CARM in Q2 2018 and held it in 3 quarters. The position peaked at $55K in Q2 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q1 2019.

  • Brown Advisory reported no remaining Carisma Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Brown Advisory sold 1,044 Carisma Therapeutics shares in Q1 2019, an estimated $30K.
  • Brown Advisory first reported a position in Carisma Therapeutics in Q2 2018 and held it in 3 quarters.
  • Brown Advisory's Carisma Therapeutics position peaked at $55K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q1 2019.

Based on Brown Advisory's 13F filing for Q1 2019, filed 15 May 2019.